Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8) and 2000-L scales (Process C, n = 3) for the production of a monoclonal antibody by a Chinese hamster ovary cell line. For the upstream part of the process, we implemented an intensified seed culture scheme to enhance cell densities at the seed culture step (N-1) prior to the production bioreactor (N) by using either enriched N-1 seed culture medium for Process B or by operating the N-1 step in perfusion mode for Process C. The increased final cell densities at the N-1 step allowed for much higher inoculation densities in the production bioreactor operated in fed-batch mode and substantially increased titers by 4-fold from Process A to B and 8-fold from Process A to C, while maintaining comparable final product quality. Multiple changes were made to intensify the downstream process to accommodate the increased titers. New high-capacity resins were implemented for the Protein A and anion exchange chromatography (AEX) steps, and the cation exchange chromatography (CEX) step was changed from bind-elute to flow-through mode for the streamlined Process B. Multi-column chromatography was developed for Protein A capture, and an integrated AEX-CEX pool-less polishing steps allowed semi-continuous Process C with increased productivity as well as reductions in resin requirements, buffer consumption, and processing times. A cost-of-goods analysis on consumables showed 6.7-10.1 fold cost reduction from the conventional Process A to the intensified Process C. The hybrid-intensified process described here is easy to implement in manufacturing and lays a good foundation to develop a fully continuous manufacturing with even higher productivity in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467 · cited 1×
“that mAbs with non-Man5 and 5% Man5 exhibited little difference in half-life in human.(50) It should be noted that Man5, G1F, and G2F are not expected to have any effect on the mechanism of action, as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity are not involved for this specific…”
BackgroundZhu, M. M., Goyal, A., Rank, D. L., Gupta, S. K., Boom, T. V., & Lee, S. S. (2008) · Biotechnology Progress · doi:10.1021/bp049815s · Cited by 199 · cited 1×
“Nonetheless, <100 mmHg CO2 has been commonly observed in large-scale cell culture processes and is generally considered to have no negative impact on cell culture, which is in agreement with another report.(49)”
Result
Cited by
Wasalathanthri, D. P., Rehmann, M. S., Song, Y., Gu, Y., Mi, L., Shao, C., Chemmalil, L., Lee, J., Ghose, S., Borys, M. C., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27461 · Cited by 177
Self-citationBioprocessing 4.0 in Biomanufacturing: Paving the Way for Sustainable Bioeconomy
Pandey, K., Pandey, M., Kumar, V., Aggarwal, U., & Singhal, B. (2024) · Systems Microbiology and Biomanufacturing · doi:10.1007/s43393-023-00206-y · Cited by 58
“Currently, four intensification schemes, viz. seed train intensification, concentrated fed-batch production, dynamic perfusion, and single-use technologies have been used in upstream processing [25].”
Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., et al. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1998821 · Cited by 55
“reporting comparable product quality rather than any improvements or changes [18,53,96,97,99,129].”
BackgroundSchulze, M., Lemke, J., Pollard, D., Wijffels, R. H., Matuszczyk, J., & Martens, D. E. (2021) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2021.06.011 · Cited by 34
Process analytics 4.0: A paradigm shift in rapid analytics for biologics development
Wasalathanthri, D. P., Shah, R., Ding, J., Leone, A., & Li, Z. J. (2021) · Biotechnology Progress · doi:10.1002/btpr.3177 · Cited by 17
“, productivity), which significantly reduce manufacturing costs and facility footprints through the adoption of innovative technologies.(2) For instance, intensified downstream processes often”
BackgroundSelf-citation
Metadata
- Authors
- Xu, J., Xu, X., Huang, C., Angelo, J., Oliveira, C. L., Xu, M., Xu, X., Temel, D., Ding, J., Ghose, S., Borys, M. C., & Li, Z. J.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 12
- Issue
- 1
- Pages
- 1770669-1770669
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W3026830821
- Cited by
- 89
- References
- 4
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study. https://app.cochat.ai/papers/10.1080/19420862.2020.1770669
- The paper
- Xu, J., Xu, X., Huang, C., Angelo, J., Oliveira, C. L., Xu, M., Xu, X., Temel, D., Ding, J., Ghose, S., Borys, M. C., & Li, Z. J. (2020). Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study. mAbs. https://doi.org/10.1080/19420862.2020.1770669
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.